Valeant Pharmaceuticals International Stock Price and Value Analysis

Should you buy Valeant Pharmaceuticals International stock? (NYSE:VRX). Let's see how it does in our automated value investing analysis system.

  • This company is not making money.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

VRX Free Cash Flow Trend

Hmm, we can't give any reliable projection for Valeant Pharmaceuticals International's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for VRX
Free Cash Flow trendline for Valeant Pharmaceuticals International

Inside the VRX Numbers

VRX Price
(Valeant Pharmaceuticals International stock price per share)
[?] PE Ratio versus Sector 87% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Drug Manufacturers - Specialty & Generic stocks
[?] Cash Yield -0.13%
[?] Free Cash Flow Jitter 51%

Is Valeant Pharmaceuticals International Stock on Sale?

Based on our analysis, we believe that you should not buy Valeant Pharmaceuticals International right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy VRX Stock?

Does Valeant Pharmaceuticals International have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.